Tags : Geron

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

Vartika Singh January 3, 2020

The biopharma industry saw a significant increase in the number of deal terminations in the last two years. Clinical and regulatory results, change in control limitations, and strategic reprioritizations were among the most common reasons for deal termination. We used the DealForma database to track partnership terminations announced in 2018 and 2019. We compiled a […]Read More

Biotech

Janssen Terminates Development and Commercialization Agreement with Geron for Imetelstat

Vartika Singh September 28, 2018

Shots: The termination of 2014 deal, is based on evaluation of portfolio and prioritization of assets within Janssen’s portfolio Janssen to support Geron involving transfer of ongoing clinical trials, regulatory, medical affairs, manufacturing and preclinical activities for 12 months and supply imetelstat for clinical manufacturing for up to 24 months Imetelstat is currently evaluated in […]Read More

Takeda Enters into an Exclusive License Agreement with Mirum to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan

Amgen Collaborates with Verastem to Evaluate VS-6766 + Lumakras (Sotorasib) in P-I/II Trial for KRAS G12C-Mutant Non-Small Cell Lung Cancer

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

AbCellera Enters into a License Agreement with Everest to Discover Antibody Therapies

Samsung Bioepis and Biogen’s Byooviz (biosimilar, ranibizumab) Receives the US FDA’s Approval for the Treatment of Retinal Vascular Disorders

Samsung Bioepis Reports Results of Post-Hoc Analysis from P-III Study of Byooviz (biosimilar, ranibizumab) for the Treatment of nAMD

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Incyte’s Jakafi (ruxolitinib) Receives the US FDA’s Approval for the Treatment of Chronic Graft-Versus-Host Disease

Innovent Reports NMPA’s Acceptance of sNDA for Sintilimab as 1L Treatment for Esophageal Squamous Cell Carcinoma

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Vigeo Reports Completion of VT1021 in P-I/II Study for the Treatment of Recurrent Glioblastoma and Pancreatic Cancer

Tags : Geron

Top Biopharma Deal Terminations of 2018-2019 by Total Value Received

Janssen Terminates Development and Commercialization Agreement with Geron for Imetelstat

Latest Posts

ViewPoints Article: 5 Technologies That Redefines Human Medicine and Therapeutics

Immunic Sign a License Agreement with University Medical Center Goettingen for IMU-838 & N4-Hydroxycytidine to Treat Viral Infections

Gilead Reports Results of Veklury (remdesivir) in P-III Trial for the Treatment of COVID-19

Incyte’s Jakafi (ruxolitinib) Receives the US FDA’s Approval for the Treatment of Chronic Graft-Versus-Host Disease

Tags : Geron

Latest Posts

Categories

Related Topics